GRAIL to Announce Second Quarter 2026 Financial Results
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) will release its second quarter 2026 financial results after the market close on Wednesday, August 5, 2026. Company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to review the results and discuss business progress.
According to GRAIL, live and replay webcasts will be accessible via the investor relations section at investors.grail.com. Interested participants are asked to register for the live event in advance and join at least ten minutes before the scheduled start.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Earnings date notice | Neutral | -3.7% | Prior quarter-results scheduling notice preceded a 3.71% 24-hour share-price decline. |
| Feb 16 | Earnings date notice | Neutral | +1.6% | Full-year results scheduling notice preceded a 1.57% 24-hour gain in the observed record. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific history was mixed, with one negative and one positive reaction; its provided average move was -1.07%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Second Quarter 2026 Webcast and Conference Call Details
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.
Please register for the live event at https://grail-q2-financial-results-2026.open-exchange.net/.
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-second-quarter-2026-financial-results-302838133.html
SOURCE GRAIL, Inc.